Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its experimental contraceptive pill, NOMAC-E2 with combination of 1.5mg of 17-beta-estradiol with 2.5mg of nomegestrol acetate in a 24/4 monophasic regimen.
Subscribe to our email newsletter
Teva Pharma said that the positive opinion was based on the significant results from the clinical trials evaluating, NOMAC-E2.
NOMAC-E2 is a monophasic regimen containing an estrogen which is structurally identical to the major estrogen produced by the ovaries of healthy non pregnant women, combined with a selective progesterone analogue (nomegestrol acetate).
If approved for marketing by the European Commission, NOMAC-E2 will be marketed by Teva/Theramex in select European markets.